

## Quality Control Assessment of Different Brands of Ciprofloxacin 500 mg Tablets in Yemen

### ABSTRACT

**Background:** Ciprofloxacin is a fluorinated 4-quinolone or fluoroquinolone antibacterial with a wider spectrum of activity than nalidixic acid and more favorable pharmacokinetics allowing its use in systemic infections. It has been used in the treatment of a wide range of infections. Many different brands and dosage forms of Ciprofloxacin hydrochloride are available in the Sana'a market that places health practitioners in a dilemma of drug substitution in case of non-availability of a particular brand.

**Aim/Objective:** The aim of the present study was to evaluate the quality control of five brands of Ciprofloxacin hydrochloride tablets marketed and commonly prescribed in Sana'a city. The results and findings of the present study will be interpreted and discussed.

**Materials and methods:** Five brands of Ciprofloxacin hydrochloride tablets (500 mg) were purchased from the retail pharmacy outlets and their pharmaceutical quality were assessed by using in-vitro tests as per the British Pharmacopoeia (BP) and unofficial standards as recommended by the manufacturers. The assessment of tablets included the evaluation of uniformity of weight, friability, hardens, disintegration time, dissolution test and assay content by UV spectrophotometric method.


**Results:** All brands passed USP and BP standards in- vitro quality control tests prescribed for the tablets except hardens test but the all products were satisfactory for hardness.

**Conclusion:** The results indicated that the overall quality of all tested Ciprofloxacin hydrochloride tablets brands was satisfactory as they met the requirements of the official and unofficial quality control tests.

**Keywords:** quality control, Ciprofloxacin HCl, dissolution, disintegration, hardens, friability

### 1. Introduction

Ciprofloxacin is a synthetic fluoroquinolone derivative with broad spectrum antibacterial activity [1]. It is widely used in the treatment of urinary tract infections, lower respiratory tract infections, bacterial diarrhoea, skin and soft tissue infections, bone and joint infections, gonorrhoea, and in surgical prophylaxis [2]. In most of the cases, it would appear that for treatment of above said infections, physicians prescribe ciprofloxacin as a first choice of drug. Ciprofloxacin (CIP) is fluoroquinolone with fluorine at position 6 of naphthyridine ring. The chemical structure of ciprofloxacin is shown in Figure 1 [3].



**Figure 1. Chemical structure of ciprofloxacin.**

Quality control is all measures designed to ensure the output of uniform batches of drugs that conform to established specifications of identity, strength, purity, and other characteristics [4]. According to pharmaceutical manufacturers association of U.S. "quality is the sum of all the factors which contribute directly or indirectly to the safety, effectiveness and acceptability of the

product” [5]. Also, quality control is the part of Good Manufacture Practice (GMP) that is concerned with sampling, specifications, testing, documentation and release procedures which ensure that the necessary and relevant tests are actually carried out and that the materials are not released for use, not products released for sale or supply, until their quality has been judged to be satisfactory [6].

A comprehensive evaluation, however, involves the determination of uniformity of weight, chemical content, friability, hardness, and disintegration tests along with dissolution rate. Drugs that are chemically and biopharmaceutically equivalent must be identical in strength, quality, and purity. The content uniformity, disintegration, and dissolution rates must be comparable [7].

The United States Pharmacopoeia [8] describes an HPLC method for CIPRO and CIPRO HCl assay in bulk, CIPRO injection, ophthalmic ointment, ophthalmic solution and tablets. Despite most methods presented in official compendia are physicochemical assays, these methods do not represent the potency of antimicrobials neither can predict the loss of activity.

The aim of the present study is to evaluate the quality of different brands of Ciprofloxacin tablets.

## 2. Materials and Methods

### 2.1. Materials

Comparative in-vitro quality control parameters between six commercially available tablet different brands of ciprofloxacin were purchased from the retail pharmacies in Sana'a, Yemen. All brands were studied through the evaluation of weight variation, drug content, hardness, friability, disintegration time and dissolution profile. All the tablet brands of ciprofloxacin were labeled to contain 500 mg of ciprofloxacin per tablet and coded as A, B, C, D, and E (table 1). The study was done by performing various test procedures associated to assess the quality of tablets. USP and British pharmacopoeia were used as standard for the evaluation study.

**Table 1. Brands of Ciprofloxacin**

| Code Brand | Country of origin | Strength in mg | Batch number |
|------------|-------------------|----------------|--------------|
| A          | Yemen             | 500            | 12669        |
| B          | Yemen             | 500            | 13219        |
| C          | Yemen             | 500            | 1991         |
| D          | India             | 500            | 1301         |
| E          | India             | 500            | FD3175       |

### 2.2. Methodology:

Various analytical methods and tests are important for the development and manufacture of pharmaceutical formulations. The evaluation was done according to USP and BP standards.

#### 2.2.1. Weight Variation

Twenty (20) tablets from each of the brands were weighed individually using an analytical weighing balance. The average weight for each brand as well as percentage deviations were calculated.

#### 2.2.2. Drug content

The estimation of drug content for ciprofloxacin tablets was performed by crushing three tablets and quantity equivalent to 45 mg was taken and determined using 0.1M HCl using UV spectrophotometer at about 276 nm,

### 2.2.3. Hardness Test

A tablet was placed vertically on the Monsanto Hardness tester. The load was then applied along the radial axis of the tablet. The weight or load required for breaking the tablet was noted down. Similarly it was done for 10 tablets.

### 2.2.4. Friability

It was performed using Roche Friabilator, 10 tablets were weighed and placed in apparatus. The apparatus was rotated at a speed of 25 rpm. The apparatus was made to rotate for 4 min. The tablets were reweighed ( $W_2$ ) and compared with their initial weights and percentage friability was obtained. Percentage friability was calculated as:

$$\text{Percentage friability} = [(W_1 - W_2) / W_1] \times 100\%.$$

### 2.2.5. Disintegration Test

Six (6) tablets from each brand were employed for this test in a freshly prepared medium, 0.1N HCl at 37°C using the BP disintegration apparatus. The disintegration time was taken to be the time no particle remained on the basket of the system.

### 2.2.6. Dissolution Test

The dissolution test was carried out using USP apparatus II (paddle method) 5 in 6 replicates for each brand. The dissolution medium was 900 mL 0.1N HCL which was maintained at 37± 0.5°C. In all the experiments 5 mL of dissolution sample was withdrawn at 0, 10, 20, and 30 min and replaced with equal volume of dissolution medium to maintain sink condition. The sampling times were selected in due consideration for the short disintegration times. Samples were filtered and assayed by ultraviolet spectrophotometry at 276 nm. The concentration of each sample was determined from a predetermined calibration curve for ciprofloxacin hydrochloride.

### 2.2.7. Data processing and analysis

After the completion of all test procedures data for all the individual tablets were recorded and separated on a different sheets according to the manufacturer. Finally, data were analyzed by using the above mentioned mathematical formula and MS-Excel®, 2007.

## 3. Results and Discussion

### 3.1 General aspect

The present study was conducted to assess the quality of 500 mg ciprofloxacin tablets marketed in Sana'a Yemen. To achieve this purpose, four different pharmaceutical companies (brands) A, B, C, D, and E were used (see table 1). They were obtained from different retail pharmacies in Sana'a and then were subjected to a number of tests. A quality control study is very important to evaluate tablet properties. Different quality control parameters (e.g., weight variation, drug content uniformity, hardens, friability, disintegration time and dissolution tests) were performed to determine the differences among various conventional ciprofloxacin tablets that are available in the Yemeni drug market.

### 3.2. Average Weight and Weight Variation:


Although the uniformity of weight does serve as a pointer to good manufacturing practice (GMP) as well as amount of the active pharmaceutical ingredients, especially for reproducibility of the product which is very essential for mass production of any product.

The average weight and weight variation of the different brands of ciprofloxacin tablets tested are shown in Tables 3.1 and Fig.3.1. It was found that the average weight of different five brands tablets of ciprofloxacin tablets ranged from 679.3 mg ± 2.63 % (A brand) to 842.7 mg ± 3.58 % (E brand), while the deviation from average weight for all product is not more than 3.58 %.

Therefore, all the five brands tested in this study complied with the compendia specification for uniformity of weight which states that for tablets weighing more than 324 mg, weight of not more than 2 tablets should not differ from the average weight by more than 5% [9]. Thus, all brands passed the weight uniformity test set by USP. Also, the results indicate the use of different excipients with different weights.

**Table 2. Average weight, % deviation from average weight, content uniformity, and % deviation from content uniformity of different brands of ciprofloxacin tablets.**

| Brands | Average weight (mg) ,<br>% RSD | Content uniformity (%),<br>% RSD |
|--------|--------------------------------|----------------------------------|
| A      | 679.3 ± 2.63                   | 98.10 % ± 2.2990                 |
| B      | 758.3 ± 1.07                   | 101.3 % ± 0.897544               |
| C      | 809.6 ± 1.57                   | 101.34 % ± 3.264                 |
| D      | 812.5 ± 1.70                   | 100.30 % ± 3.607                 |
| E      | 842.7 ± 3.6                    | 101.40 % ± 0.3778                |



**Figure 2. Comparison of different brands weight variation of different brands of ciprofloxacin tablets.**

### 3.3. Content Uniformity (Assay)

Every unit of tablet should contain the amount of drug substance equivalent to its label amount. For the evaluation of content, assay should be performed. The weight variation test is simplified and alternative to content uniformity test to assure therapeutic utility [10] and is an indicator of variations in the drug content [11]. The average chemical content (assay) values of the different brands of ciprofloxacin tablets tested shown in table 2 and figure 3. The results of the assay of chemical content of ciprofloxacin tablets showed that the active content of all the brands were between  $98.10 \pm 2.2990$  % (A brand) and  $101.40 \pm 0.3778$  % (E brand) of the labeled amount specified for ciprofloxacin tablets. A and B brands were chemically equivalent because they had chemical content not less than 90 % and not more than 100 % (w/w) [12]. According to the United State Pharmacopoeia [13], ciprofloxacin tablets should contain not less than 90 % and not more than 110 % of ciprofloxacin tablets. The results indicated that although different manufacturer formulates the different brands are under the BP/USP specification [14]. Furthermore, all the

brands of the tablets passed the test for the content of ciprofloxacin tablets. All these brands fall within the British Pharmacopoeia Specification of 95 % – 105 % [15].




Figure 3. Comparison of assay content (Percent %) of different brands of ciprofloxacin tablets.

### 3.4. Hardness Test:


The crushing strength of the tablets is an essential criterion in the determination of the ability of the tablets to resist chipping, abrasion or breakage under conditions of storage, transportation and handling before storage [16]. Hardness, which is now more appropriately called crushing strength of the tablet is determined to make adjustments to the pressure in the tablet press [17]. It can also influence other parameters such as friability and disintegration [18].

The average values of hardness of the different brands of ciprofloxacin tablets tested shown in table 3 and figure 4. Average hardness was found in the range of 20.03 kg/cm<sup>2</sup> (A brand) to 31.535 kg/cm<sup>2</sup> (E brand). The results indicated that all brands of ciprofloxacin tablets were not in the limit range of between 4 to 10 kg/cm<sup>2</sup> stated [ [17, 19]. Where all brands were greater than 20 kg/cm<sup>2</sup>. The hardness of the tablets showed that all brands gave the highest crushing strength.

Hardness is referred to as non-compendial test. The hardness or crushing strength assesses the ability of tablets to withstand handling without fracturing or chipping. It can also influence other parameters such as friability and disintegration. Normally, a force of about 4 kgs is the minimum requirement for satisfactory tablets [20]. Therefore, the tablets of all products were satisfactory for hardness.

**Table 3. Hardness (kg/cm<sup>2</sup>), % deviation from hardness, friability percent (%) , disintegration time (min), dissolution (30 min), % deviation from dissolution of different brands of ciprofloxacin tablets.**


| Brands | Hardness (kg/cm <sup>2</sup> )<br>% RSD | Friability (%) | Disintegration time (min) | Dissolution (30 min),<br>% RSD |
|--------|---|----------------|---------------------------|--------------------------------|
| A      | 20.03 (±14.397)                         | 0.36           | 1.41                      | 99.33 (±2.03711)               |
| B      | 27.41 (±7.98681)                        | 0.37           | 3.16                      | 100.15 (±1.4314)               |
| C      | 25.585 (±8.3994)                        | 0.12           | 3.51                      | 98.15 (±1.796)                 |
| D      | 23.35 (±8.16783)                        | 0.013          | 1.41                      | 96.4 (±1.16786)                |
| E      | 31.535 (±7.37343)                       | 0.06           | 4.15                      | 98.00 (±1.2712)                |



**Figure 4. Comparison of hardness of different brands of ciprofloxacin tablets.**

### 3.5. Friability Test:

Tablet hardness is not the absolute indicator of the tablet strength since some formulations when compressed to very hard tablet tend to cap or laminate on attrition losing their crown part. Therefore, another measure of the tablet strength, its friability is often measured. The loss due to abrasion is a measure of the tablet friability. The average values of friability of the different brands of ciprofloxacin tablets tested shown in table 3 and figure 5. The average values of friability ranging from 0.01 % (D brand) to 0.37 % (B brand). The friability was less than 0.5 %, indicating that it is within the compendia limits, which showed that the tablets possess good mechanical strength. Also, this showed that all the brands could withstand abrasion without loss of tablet integrity, and the causes of high friability were taken in consideration during manufacturing the tablet. Namely tablets compressed with larger force tend to have slightly lower friability compared with the ones compressed with smaller force [21]. The pharmacopoeia [20] states that the friability value of tablets should be less than 1% and as such all the brands of ciprofloxacin had passed this friability specification



**Figure 5. Comparison of friability percent (%) for different brands of ciprofloxacin tablets.**

### 3.6. Disintegration Time:

Tablet disintegration time is one of the very important physicochemical properties in solid dosage forms. The disintegration test measures the time required for tablets to disintegrate into particles. This is a necessary condition for dissolution and could be the rate-determining step in the process of drug absorption. The average values of disintegration of the different brands of ciprofloxacin tablets tested shown in table 3 and in figure 6. The results of disintegration time (min) of ciprofloxacin tablets were ranging from 1.41 min (A and D brands) to 4.15 min (E brand). All brands of the ciprofloxacin tablets passed the pharmacopoeia [22] standard which stipulates a disintegration time of not more than 15 minutes for uncoated tablets, while USP specification for disintegration is 30 min both for uncoated and film coated tablets. All the brands were complied with the both BP and USP specifications. All the brands were complied with the both BP and USP specifications. The rapid disintegration time exhibited by all the brands might be due to type and amount of disintegrant used in the formulation. All the disintegration times had fallen within the acceptable range.




Figure 6. Comparison of disintegration time (min) of different brands of ciprofloxacin tablets.

### 3.7. Dissolution Test


The process of dissolution plays a vital role in liberation a drug from its dosage form and making it available for subsequent gastrointestinal absorption. So, dissolution analysis of pharmaceutical solid dosage forms is a very important test of product quality and it can be used as a sensitive method for differentiating between formulations of the same therapeutic agent [23 – 24].

Drugs with poor dissolution profile will not be available in the body system to elicit therapeutic effect [25]. Also, the dissolution study was carried out to determine the resistance of the materials the acidic environment of the stomach and their suitability as enteric coating materials. The drug release study is a measure of the amount of the drug released into the dissolution medium with time. This study gives an idea of amount of drug available for absorption after oral administration. Drugs with poor dissolution profile will not be available in the body system to elicit therapeutic effect [25].

The average values of dissolution of the different brands of ciprofloxacin tablets tested shown in table 3 and graphically in figure 7. The obtained dissolution content at 30 minutes was found to be ranged from 96.48 %  $\pm$  1.168 % to 100.15 %  $\pm$  1.4314 %. All brands of ciprofloxacin tablets showed more than 90 % drug release after 30 minutes. At 30 mins, all the brands released more than the pharmacopoeia (USP 30, NF 25) requirement of 70 % active pharmaceutical ingredient [20]. All the brands of the ciprofloxacin hydrochloride tablets complied with the official



specification for content uniformity having between 92-104% as stipulated by the USP. This might be as a result of strict adherence to good manufacturing practice in the process of manufacturing these tablets.



**Figure 7. Comparison of dissolution test of different brands ciprofloxacin tablets.**

### Conclusion

From the present study, it was clearly demonstrated that all five brands of the ciprofloxacin hydrochloride tablet comply with BP and USP specifications for in vitro quality control tests of uniformity of weight, uniformity of content, friability, disintegration time, and dissolution except hardens test for five brands. The USP and BP specification of maximum hardens value of 10 kg/cm<sup>2</sup>, where the lower value of hardens is 20.03 kg/cm<sup>2</sup> and the value is 31.535 kg/cm<sup>2</sup>. But Hardness is referred to as non-compendial test.

Finally, bioequivalence studies are essential and important. Also such studies may be more important in developing countries where counterfeit and substandard drugs have become a major challenge to health care services.

### References

- [1]. Tripathy KD: Sulfonamides, cotrimoxazole and quinolones, In: Essentials of Medical Pharmacology. Jaypee Brothers Medical Publishers (P) Ltd, New Delhi, India, Edition 5, 2003: 646-652.
- [2]. Hervey SC: Antimicrobial drugs, In: Gennaro AR, Editor, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania 18042, Edition 18, 1991: 1163-1241
- [3]. Muhammad Nasimulah Qureshi, Inayat UR Raahman and Gul Akhtar Marwat. Comparative analysis of Ciprofloxacin in different Pharmaceutical products by High Performance Liquid Chromatography. *Sci., Tech. and Dev.*, 31 (1): 69-73, 2012
- [4]. World Health Organization, Guidelines for developing national drug policies, Geneva, 1988
- [5]. Verpoorte R, Mukherjee PK. GMP for botanicals: regulatory and quality issues on phytomedicines. 1st ed. Business Horizons; 2003. p.60.
- [6]. World Health Organization and Cairo university, Guidelines for good manufacturing practice of pharmaceuticals in Egypt, Faculty of pharmacy, Cairo University, Central administration of pharmacy, WHO, Cairo, 1994.



- [7]. Dressman, J. B., Amidon, G. L., Reppas, C.; Shah, V. P. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. *Pharm. Res.*1998, 15 (1), 11–22.
- [8]. The US Pharmacopeia, 30ed., the US Pharmacopoeial Convention, Rockville, 2007.
- [9]. Ngwuluk NC, lawal K, Olorunfemi PO, Ocheke NA. Post-market in vitro bioequivalence study of six brands of ciprofloxacin tablets/caplets. *Sci. Res. Essay*(2009) 4: 298 – 305.
- [10]. Lachman L, Liberman H, Kanig J. *The Theory and Practice of Industrial Pharmacy*; Third Edition: 293-345, 346-373.
- [11]. Aulton M. *Pharmaceutics: The Science of Dosage Form Design*. International Student Edition: 304-321, 347-668.
- [12]. The United States Pharmacopoeial Convention, United States Pharmacopoeia 30. Acetaminophen, The United States Pharmacopoeial Convention, Rockville. USA, 2006.
- [13]. Bradoo R, Shahani S, Deewan B, Sudarshan S. Fast dissolving drug delivery system. *J Am Med Assoc India*, 2001; 4 (10): 27-31.
- [14]. Willard-Hobart H, Merritt Jr Lynne L, Dean John A (1974) *Instrumental Methods of Analysis*. (5th edn), Von Nostrand, University of Michigan.
- [15]. Milton, A.S., Wendlandt, S. A., (1970), possible role for prostaglandin E1 as a modulator of temperature regulation in the central nervous system of the cat. *J Physiol*; 207:76–7. <http://www.pubmedcentral.nih.gov/articlerender.fcgi>. (Last accessed August 6, 2008).
- [16]. Davidson AG (2002) Ultraviolet-visible absorption spectrophotometry. In Beckett AH, Stenlake JB, (4th edn), *Practical Pharmaceutical chemistry*. CBS Publishers and distributors, New Delhi, 275-278.
- [17]. Rawlins, E.A. (1977). Bentley's text book of pharmaceuticals (8th ed., pp. 289-290), Bailliere Tindal publisher.
- [18]. Tanjinatus Shams Oishi, Md. Ahsanul Haque, Irin Dewan, and S. M. Ashraful Islam. COMPARATIVE IN VITRO DISSOLUTION STUDY OF SOME CIPROFLOXACIN GENERIC TABLETS UNDER BIOWAIVER CONDITIONS BY RP-HPLC. Oishi et al., *IJPSR*, 2011; Vol. 2(12): 3129-3135
- [19]. H.M. Ali,; M.M. A. Homeida,; J. Ford,; C.A. Truman,; C.J.C. Roberts,; and A.A. Badwan, (1988). *Int. J. Pharm.*, 42,155-159
- [20]. The United State Pharmacopoeia. *USP 30 - NF25*, the official compendia of standards 2007, 1755 – 1759.
- [21]. Perioli L, Ambrogi V, Angelici F, Ricci M and Giovagnoli S, “Development of Mucoadhesive Patches for Buccal Administration of Ibuprofen.” *Journal of Control Release*. 2004, 99, 73-82.
- [22]. *British Pharmacopoeia* (2002). Her majesty's Stationery office, University Press Cambridge, Vol. 1 and 2.
- [23]. Hsu H and Ayres JW: Chlorpheniramine Dissolution and Relative Urinary Excretion from Commercial Products. *Journal of Pharmaceutical Sciences* 1989; 78(10): 844-47.
- [24]. Brunton LL: *The pharmacological Basis of Therapeutics*. Gilman AG, Ra TW, Nies AS and Taylor P (ed), pergamon press. Singapore, Edition 8, 1991: 926-928.
- [25]. Tapan Kumar Giri, Neha Parveen, Deepa Thakur, Amit Alexander, Ajazuddin, Hemant Badwaik and Dulal Krishna Tripathi. In vitro Evaluation of Commercially Available Enteric Coated Tablet Containing Diclofenac Sodium. *International Journal of Research in Pharmaceutical and Biomedical Sciences*, Vol. 3 (2) Apr – Jun2012, p. 875 – 881.